PHARMAC has decided not accept any proposals for the supply of insulin glargine following consideration of responses to the request for proposals (RFP) for insulin glargine issued on 22 February 2016.
We consulted on a draft strategy. Here's your feedback.
Steffan Crausaz, PHARMAC Chief Executive, would like to take the time to wish pharmacists from all over New Zealand #happyworldpharmacistsday for Sunday 25 September.
PHARMAC is seeking feedback from DHB hospitals, suppliers and other interested parties on a draft tender list of intravenous (IV) fluid bags and a range of irrigation solutions, collectively referred to as bulk fluids, to be included in upcoming national procurement activity.
To provide feedback, please submit it in writing, preferably in the excel file supplied, or as a separate document clearly referencing the item number relevant to each aspect of your feedback. All responses are due by 5pm Thursday 27 October 2016.
PHARMAC is pleased to announce the approval of proposals to:
- Amend the Pharmaceutical Schedule rules to support the new prescribing rights that have been granted to Registered Nurse Prescribers.
- Amend the ‘Retail Pharmacy - Specialist’ restriction to support prescribing of these products by Nurse Practitioners.
Information about vacancies at PHARMAC is now available on our careers site.
Read the site and register with us to hear about vacancies as they come up.
PHARMAC is seeking feedback on a proposal to list a new treatment for HIV, dolutegravir (Tivicay) and to amend the listing of a currently funded HIV treatment, abacavir sulphate with lamivudine (Kivexa). This proposal has arisen as a result of a provisional agreement with GlaxoSmithKline NZ Limited. PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by 9am Friday, 23 September 2016.
PHARMAC is seeking feedback on a proposal to list the Midazolam-Claris brand of midazolam injections in Section B of the Pharmaceutical Schedule from 1 December 2016 through an agreement with AFT Pharmaceuticals. PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Tuesday, 20 September 2016.
PHARMAC is asking New Zealanders to help it make some changes to how medicine and medical device funding applications are made.
PHARMAC’s implementation of Trans-Pacific Partnership (TPP) provisions and other amendments to application processes
PHARMAC is seeking feedback on our proposed approach to addressing New Zealand’s obligations under the Trans-Pacific Partnership (TPP) Agreement.
PHARMAC is pleased to announce a decision to award a sole supply arrangement for leflunomide to Apotex NZ Limited for its Apo-Leflunomide brand from 1 June 2017 in DHB hospitals and from 1 September 2017 in the community.
Following a Request for Proposals (RFP) for the supply of anti-endothelial growth factor (anti-VEGF) agents for ophthalmic use (primarily wet aged macular degeneration (wAMD)) issued on 5 May 2016, PHARMAC has entered into provisional agreements with Novartis New Zealand Limited and Bayer New Zealand Ltd and is seeking feedback on a proposal to award Hospital Supply Status from 1 November 2016 until 31 October 2019.
To provide feedback, please submit it in writing by 5pm on Monday 19 September 2016.
PHARMAC is seeking feedback on which categories of hospital medical devices it should focus on next as part of its medical devices programme of work. We expect to be able to begin work in new product categories in the next 12 months.
We would like to start collating the feedback in September, therefore would appreciate all responses by Friday, 30 September 2016.
PHARMAC has resolved to award tenders for Sole Subsidised Supply Status and Hospital Supply Status for some products included in the 2015/16 Invitation to Tender, dated 6 November 2015.
PHARMAC has made decisions to award the Zoladex brand of goserelin Sole Subsidised Supply in the community and Hospital Supply Status in DHB hospitals and to apply reference pricing to leuprorelin (Eligard and Lucrin) in the community.
PHARMAC is seeking feedback on a proposal to fund a new formulation of enteral feed for dietary management of patients with low energy and/or low fluid requirements. This proposal is as a result of a provisional agreement with Nutricia Limited. PHARMAC welcomes feedback on this proposal. To provide feedback, please submit it in writing by Monday, 12 September 2016.
Agreement with Ivoclar Vivadent Limited for the supply of sterilisation packaging products and associated consumables
PHARMAC is pleased to announce the approval of an agreement with Ivoclar Vivadent Limited (“Ivoclar Vivadent”) for the supply of sterilisation packaging products and associated consumables.
Please note – The web version of the consultation document dated 10 August 2016 has been amended on 18 August 2016 to make it consistent with the consultation document pdf that was emailed to interested parties on 10 August 2016. This revised web version of the consultation document amends the pack size from a 90 pack to a 84 pack. In consideration of this amendment, PHARMAC extends the period to submit feedback on this proposal until Thursday 01 September 2016.
Venlafaxine is listed in the antidepressants sub-group of the Nervous System Therapeutic Group in the Pharmaceutical Schedule.
Following a Request for Tender (RFT) for the supply of venlafaxine issued on 15 June 2016, PHARMAC is seeking feedback on a proposal to
- award Sole Supply Status in the community for venlafaxine to Mylan New Zealand Limited (Mylan) for its Enlafax XR brand of modified-release capsules: 37.5 mg, 75 mg and 150 mg from 1 September 2017 until 30 June 2020.
award Hospital Supply Status for venlafaxine to Mylan for its Enlafax XR brand of modified release capsules: 37.5 mg, 75 mg and 150 mg from 1 June 2017 until 30 June 2020, with a 1% DV limit.
PHARMAC’s decisions affect nearly all New Zealanders, and the Government pharmaceutical funding agency is asking people to help it make some changes to how medicine and medical devices funding applications are made.
PHARMAC is inviting proposals for the supply of diabetes management products (blood glucose and blood ketone meters and their test strips) in New Zealand.
This request for proposals is the second and final stage of a two stage procurement process following an expression of interest that was issued on 29 June 2015 (EOI).
NOTE: Only those suppliers who responded to the Expression of Interest and whose meters have completed the specified laboratory testing are invited to participate in this request for proposals.
If you wish to submit a proposal, you must submit it to PHARMAC via the Government Electronic Tenders Service (GETS) no later than 4.00 p.m. on 8 September 2016.